REAL WORLD EXPERIENCE OF FINGOLIMOD IN MULTIPLE SCLEROSIS: THE LONDON AUDIT

Background Fingolimodis a licensed and NICE-approved disease modifying therapy (DMT) for people with relapsing multiple sclerosis (pwRMS). Objective To analyse the ‘real world’ experience of Fingolimodin two MS centres (Barts Health and King9s College). Methods Patients were identified through electronic medical records (March 2013–December 2015). Demographics, MS history and follow-up data were analysed. Results 215 pwRMS were prescribed Fingolimodas second-line DMT in 77.6% (n=167) and first-line in 21% (n=45). 71.6% switched from Interferon-beta or Glatiramer acetate. Thirteen JCV positive pwRMS switched from Natalizumabto Fingolimod, due to risk of PML. Fingolimodwas discontinued in 15% (n=32) due to adverse effects (most frequently headache, in one case infection), pregnancy and ongoing disease activity (n=10). The absolute lymphocyte count was Conclusions Our experience of Fingolimodas a treatment for pwRMS closely resembles the data from the original phase III clinical trials and supports the short-term safety and efficacy of Fingolimodin clinical practice. This collaboration between MS centres provides useful insights into the ‘real world’ experience of benefits and risks of DMTs for pwRMS.